These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 36776664)

  • 21. A case report of drug-induced liver injury due to the infliximab biosimilar CT-P13 on switching from original infliximab in a patient with Crohn's disease.
    Kashima S; Sawada K; Moriichi K; Fujiya M
    Ther Adv Drug Saf; 2022; 13():20420986221100118. PubMed ID: 35646305
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacology and metabolism of infliximab biosimilars - A new treatment option in inflammatory bowel diseases.
    Włodarczyk M; Fichna J; Sobolewska-Włodarczyk A
    Pharmacol Rep; 2016 Aug; 68(4):797-801. PubMed ID: 27162107
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases.
    Papamichael K; Van Stappen T; Jairath V; Gecse K; Khanna R; D'Haens G; Vermeire S; Gils A; Feagan BG; Levesque BG; Vande Casteele N
    Aliment Pharmacol Ther; 2015 Nov; 42(10):1158-69. PubMed ID: 26365281
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective.
    Milassin Á; Fábián A; Molnár T
    Therap Adv Gastroenterol; 2019; 12():1756284819842748. PubMed ID: 31019554
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Great Debate With IBD Biosimilars: Con: Biosimilars Should Not Be Routinely Used as a First Line Biologic and Not Switched From Reference Biologics.
    Panaccione R
    Crohns Colitis 360; 2021 Jul; 3(3):otab038. PubMed ID: 36776671
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biosimilars in Pediatric Inflammatory Bowel Diseases: A Systematic Review and Real Life-Based Evidence.
    Dipasquale V; Cicala G; Spina E; Romano C
    Front Pharmacol; 2022; 13():846151. PubMed ID: 35370732
    [No Abstract]   [Full Text] [Related]  

  • 27. Anti-TNF Biosimilars in Inflammatory Bowel Disease: Searching the Proper Patient's Profile.
    Danese S; Fiorino G
    Curr Med Chem; 2019; 26(2):280-287. PubMed ID: 29756565
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of a medical interview on the decision to switch from originator infliximab to its biosimilar in patients with inflammatory bowel disease.
    Haghnejad V; Le Berre C; Dominique Y; Zallot C; Guillemin F; Peyrin-Biroulet L
    Dig Liver Dis; 2020 Mar; 52(3):281-288. PubMed ID: 31648920
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biosimilars in IBD: Will it Benefit to Patients, Physicians or the Health Care System?
    Gonczi L; Ilias A; Kurti Z; Lakatos PL
    Curr Pharm Des; 2019; 25(1):13-18. PubMed ID: 30864504
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease.
    Bergqvist V; Kadivar M; Molin D; Angelison L; Hammarlund P; Olin M; Torp J; Grip O; Nilson S; Hertervig E; Lillienau J; Marsal J
    Therap Adv Gastroenterol; 2018; 11():1756284818801244. PubMed ID: 30344642
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The use of biosimilars in paediatric inflammatory bowel disease.
    Jongsma MME; Vulto A; de Ridder L
    Curr Opin Pediatr; 2017 Oct; 29(5):560-565. PubMed ID: 28692448
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcomes after double switching from originator Infliximab to biosimilar CT-P13 and biosimilar SB2 in patients with inflammatory bowel disease: a 12-month prospective cohort study.
    Trystram N; Abitbol V; Tannoury J; Lecomte M; Assaraf J; Malamut G; Gagnière C; Barré A; Sobhani I; Chaussade S; Amiot A
    Aliment Pharmacol Ther; 2021 Apr; 53(8):887-899. PubMed ID: 33647174
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extrapolation and Interchangeability of Infliximab and Adalimumab in Inflammatory Bowel Disease.
    Chang S; Hanauer S
    Curr Treat Options Gastroenterol; 2017 Mar; 15(1):53-70. PubMed ID: 28164249
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy.
    Tursi A; Mocci G; Allegretta L; Aragona G; Bianco MA; Colucci R; Cuomo A; Della Valle N; Ferronato A; Forti G; Gaiani F; Graziani MG; Lorenzetti R; Luzza F; Paese P; Penna A; Pica R; Pranzo G; Rodinò S; Scarcelli A; Zampaletta C; Brozzi L; Cicerone C; Cocco A; De' Angelis G; Donnarumma L; Fiorella S; Iannelli C; Larussa T; Le Grazie M; Luppino I; Meucci C; FaggianI R; Pagnini C; Perazzo P; Rodriguez-Castro KI; Sacco R; Sebkova L; Serio M; De Monti A; Picchio M; Napolitano D; Schiavoni E; Turchini L; Scaldaferri F; Pugliese D; Guidi L; Laterza L; Privitera G; Pizzoferrato M; Lopetuso LR; Armuzzi A; Elisei W; Maconi G; Papa A
    Expert Opin Biol Ther; 2022 Feb; 22(2):313-320. PubMed ID: 34904510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD).
    Fiorino G; Caprioli F; Daperno M; Mocciaro F; Principi M; Viscido A; Fantini MC; Orlando A; Papi C; Annese V; Danese S; Vecchi M; Rizzello F; Armuzzi A;
    Dig Liver Dis; 2019 May; 51(5):632-639. PubMed ID: 30872085
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Switching from originator to biosimilar infliximab - real world data of a prospective 18 months follow-up of a single-centre IBD population.
    Høivik ML; Buer LCT; Cvancarova M; Warren DJ; Bolstad N; Moum BA; Medhus AW
    Scand J Gastroenterol; 2018 Jun; 53(6):692-699. PubMed ID: 29852793
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Update on biosimilars in inflammatory bowel disease: Position and recommendations in Mexico.
    Mayoral-Zavala A; Esquivel-Aguilar A; Del Real-Calzada CM; Gutiérrez-Grobe Y; Ramos-García J; Rocha-Ramírez JL; Rojas-Illanes MF; Rubio-Martínez B; Sánchez-Chávez X; Yamamoto-Furusho JK;
    Rev Gastroenterol Mex (Engl Ed); 2018; 83(4):414-423. PubMed ID: 29685744
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current status of biosimilars in the treatment of inflammatory bowel diseases.
    Park DI
    Intest Res; 2016 Jan; 14(1):15-20. PubMed ID: 26884730
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Infliximab Pricing in International Economic Evaluations in Inflammatory Bowel Disease to Inform Biologic and Biosimilar Access Policies: A Systematic Review.
    Bashir NS; Hughes A; Ungar WJ
    MDM Policy Pract; 2023; 8(1):23814683231156433. PubMed ID: 36860664
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biosimilars in the therapy of inflammatory bowel diseases.
    Hlavaty T; Letkovsky J
    Eur J Gastroenterol Hepatol; 2014 Jun; 26(6):581-7. PubMed ID: 24722561
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.